Specializing in bioprocessing technologies, this company develops and supplies systems, consumables, and reagents used in biologic drug manufacturing. Its products are critical for biopharmaceutical production, making it a key player in the bioprocessing supply chain that investors monitor for growth in biologics manufacturing.
4 members of Congress have disclosed 9 trades in Repligen Corporation (RGEN), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 5 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa McClain | sell | $1K – $15K |
| 2025-10-30 | Lisa McClain | sell | $1K – $15K |
| 2025-10-30 | Lisa McClain | buy | $1K – $15K |
| 2025-07-22 | Lisa McClain | buy | $1K – $15K |
| 2025-06-17 | Lisa McClain | sell | $1K – $15K |
| 2025-06-11 | Lisa McClain | buy | $1K – $15K |
| 2025-04-07 | Jefferson Shreve | sell | $15K – $50K |
| 2022-05-05 | Rohit Khanna | sell | $1K – $15K |
| 2016-02-19 | MICHAEL T. MCCAUL | buy | $1K – $15K |